Eomes-expressing T-helper cells as potential target of therapy in chronic neuroinflammation
- PMID: 30508560
- DOI: 10.1016/j.neuint.2018.11.023
Eomes-expressing T-helper cells as potential target of therapy in chronic neuroinflammation
Abstract
Reserch progresses in understanding the pathogenicity of multiple sclerosis (MS) in the last couple of decade has enabled us to develop new drug entities available in the clinic. However, we still have not succeeded in preventing conversion from relapsing-remitting MS (RR-MS) to secondary progressive MS (SP-MS) and curing this intractable form of MS. Furthermore, diagnosis is usually retrospective and subjective, relying on gradual worsening of neurological signs/symptoms. This is obviously due to the lack of understanding for the pathogenicity driving disease progression in MS and of reliable biomarkers reflecting the progressive or stationary disease status. Two relevant components are involved in brain pathology of SP-MS, neurodegeneration and inflammation. Neurodegeneration may occur spontaneously in a neuron-intrinsic manner under chronic inflammation, such as glutamate excitotoxicity, mitochondrial/oxidative injury with iron deposit in the brain, and loss of trophic support. Meanwhile, inflammation is usually associated with recurrent relapse and the cumulative infiltration of immune cells, including T cells, B cells, and myeloid cells of peripheral or CNS origin, could ignite the processes of neurodegeneration. Especially, the higher frequency of leptomeningeal follicle-like structures observed in SP-MS patients suggests that immune cells sheltered behind a blood-brain barrier is still active under smoldering CNS inflammation. Recent successes in Ocrelizumab for primary progressive in MS (PP-MS) and Siponimod for SP-MS reappraised the importance of immune cells for pathogenesis progressive MS. Accordingly, our recent comparative analysis between MS and its animal model, experimental autoimmune encephalomyelitis (EAE), raises a new possibility that ectopic expression of eomesodermin (Eomes) in helper T (Th) cells constitutes a previously unappreciated subset of Th cells with cytotoxic potential against neuronal cells. In this review article, I will summarize the mechanisms proposed on pathogenesis of SP-MS and propose a new pathogenic mechanism for neurodegeneration mediated by unique cytotoxic Th cells.
Keywords: Animal model; Diagnostic biomarker; Eomesodermin; Helper T cells; Novel therapeutic targets; Pathogenic mechanisms; SP-MS.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
-
Involvement of cytotoxic Eomes-expressing CD4+ T cells in secondary progressive multiple sclerosis.Proc Natl Acad Sci U S A. 2021 Mar 16;118(11):e2021818118. doi: 10.1073/pnas.2021818118. Proc Natl Acad Sci U S A. 2021. PMID: 33836594 Free PMC article.
-
T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis.Cells. 2020 Feb 19;9(2):482. doi: 10.3390/cells9020482. Cells. 2020. PMID: 32093011 Free PMC article. Review.
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
-
[Pathological mechanism of secondary-progressive multiples sclerosis and its animal model].Nihon Rinsho Meneki Gakkai Kaishi. 2016;39(2):103-13. doi: 10.2177/jsci.39.103. Nihon Rinsho Meneki Gakkai Kaishi. 2016. PMID: 27212596 Review. Japanese.
-
Extrapituitary prolactin promotes generation of Eomes-positive helper T cells mediating neuroinflammation.Proc Natl Acad Sci U S A. 2019 Oct 15;116(42):21131-21139. doi: 10.1073/pnas.1906438116. Epub 2019 Sep 30. Proc Natl Acad Sci U S A. 2019. PMID: 31570595 Free PMC article.
Cited by
-
Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells.Neurol Ther. 2023 Dec;12(6):2041-2052. doi: 10.1007/s40120-023-00539-9. Epub 2023 Sep 16. Neurol Ther. 2023. PMID: 37715885 Free PMC article.
-
Evaluation of Long Non-coding RNA Expression Profiles in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease.Mol Neurobiol. 2023 Nov;60(11):6201-6211. doi: 10.1007/s12035-023-03470-0. Epub 2023 Jul 12. Mol Neurobiol. 2023. PMID: 37436601
-
Biomarkers in autoimmune diseases of the central nervous system.Front Immunol. 2023 Apr 5;14:1111719. doi: 10.3389/fimmu.2023.1111719. eCollection 2023. Front Immunol. 2023. PMID: 37090723 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
